---
title: "Syndax Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $39, Implies 104% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294940410.md"
description: "Syndax Pharmaceuticals' 12-month average price target was cut to $39 from $39.45, based on estimates from 11 analysts. Despite the reduction, the target implies a 104% upside from the Aug. 4 closing price. The consensus rating remains 'Buy' across all 12 covering analysts, with no Holds or Sells reported."
datetime: "2026-08-05T09:20:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294940410.md)
  - [en](https://longbridge.com/en/news/294940410.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294940410.md)
generator: "portal-rs"
---

# Syndax Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $39, Implies 104% Upside

-   According to estimates from 11 analysts, Syndax Pharmaceuticals, Inc. stock's average price target has fallen from $39.45 to $39, with forecasts ranging from $26 to $57 per share
-   Based on the Aug. 4 closing price, the updated target implies approximately 104% potential upside
-   Consensus rating remains at “Buy” across 12 covering analysts, with 12 Buys, 0 Holds and 0 Sells

Explore more price target data and ratings for Syndax Pharmaceuticals, Inc. on the , and track all previous and future analyst recommendations for Syndax Pharmaceuticals, Inc. in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [SNDX.US](https://longbridge.com/en/quote/SNDX.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Earnings Update: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Just Reported And Analysts Are Trimming Their Forecasts](https://longbridge.com/en/news/295230452.md)
- [Syndax Pharmaceuticals (SNDX) Receives a New Rating from a Top Analyst](https://longbridge.com/en/news/293182989.md)
- [Does Interparfums’ (IPAR) Earnings Upgrade Hint At Deeper Strength In Its Profit Model?](https://longbridge.com/en/news/296564505.md)
- [Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2](https://longbridge.com/en/news/296129489.md)
- [CONMED (CNMD) Could Be 8% Overvalued Following Its Recent Rebound](https://longbridge.com/en/news/296318744.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**